The San Antonio Breast Cancer Symposium (SABCS) is celebrating its 40th year. BCRF research programs and communications teams are here to share highlights from the meeting and connect with our researchers who will be presenting at the conference.
This year over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries are attending the meeting. SABCS is unique in that its singular focus lies on breast cancer research. Researchers from all disciplines will report and learn about advances in treatment, screening and survivorship, as well as new discoveries that could lead to advances in patient care in the future. The work of BCRF investigators is highly represented in oral presentations and scientific poster presentations throughout the week.
Highlights form this year's agenda include updates from clinical trials in the new class of drugs called CDK4/6 inhibitors. Palbociclib, ribociclib and abemeciclib are all FDA approved for advanced breast cancers called estrogen receptor positive, but trials continue to test these agents in a variety of scenarios.
Another promising class of drugs we will hear more about are the PARP inhibitors. There is hope that olaparib, a PARP inhibitor approved in ovarian cancer will provide benefit to triple negative breast cancer patients, based on a similar tumor biology to ovarian cancer. Optimizing breast cancer immunotherapy with the PD-L1/ PD-1 inhibitors continues to be a major topic and we'll hear about these efforts.
As we do each year, BCRF will report highlights from BCRF investigators as well as breaking news in breast cancer research. Follow us on Facebook to catch our Facebook Live interviews with BCRF investigators who will be discussing their work on breast cancer disparities, metastatic breast cancer, male breast cancer and more.